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INTRODUCTION
Locally Advanced Breast Carcinoma represents 30-50% 
of  newly  diagnosed  Breast  Cancer  in  medically  underserved 
population all over the world1.
Historically  breast  cancer  believed  to  be  a  local 
manifestation of a systemic disorder until  Keen demonstrated 
that it began locally and spread but today it is claimed that it is 
already  disseminated  when  the  diagnosis  is  made  and  local 
treatment is useless. Most cancer at that time were huge that 
necessitated radical approach and leads to the development of 
Halsted radical mastectomy. In 1894 Keen started seeing early 
breast  cancer  and  with  3  years  follow  up  after  surgery  he 
claimed it  as cure and in 1985 Fisher claimed 5yrs result  for 
breast  preserving  operations.  With  all  developments  breast 
cancers  are   now  classified  as  early  and  advanced  breast 
carcinomas and it  becomes important to individualize patients 
for treatment best suited to a given woman. According to AJCC 
(American Joint Committee on Cancer) Cancer Staging Manual, 
Early stage invasive breast cancer – Stages I (tumor <2 cm in 
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size, axillary node-negative) and II (positive but ipsilateral and 
mobile axillary nodes, or tumor size >2 cm); a tumor >5   cm 
must  be  node-negative  to  be  considered  early  stage  Locally 
advanced  (extensive  axillary  nodal  disease,  supraclavicular 
nodal involvement, direct tumor extension to the chest wall or 
skin)  or  inflammatory  breast  cancer  -  Stage  III  disease 
Metastatic breast cancer - Stage IV disease. 
Locally advanced breast carcinoma is a clinical scenario 
considered as inoperable either because they were technically 
unresectable  or  an  extremely  high  risk  of  metastasis,  local 
recurrence and or death despite aggressive surgical resection. 
Although  multimodality  therapy  employing  combination  of 
systemic  and loco regional  therapy became the treatment  of 
choice,   the  optimal  sequencing  of  the  individual  component 
was not well defined2. Based on the concept of breast cancer as 
a  systemic  disease,  chemotherapy  was  introduced  into  the 
treatment of LABC in 1970 and more recently  major  clinical 
response to  induction chemotherapy were noted in the majority 
of patients at the time of surgery and long term outcome was 
associated with significant higher disease free survival and over 
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all  survival3.   Hence  neoadjuvant  chemotherapy  followed  by 
surgery and radiotherapy is now emerging globally as the most 
common approach for LABC including IBC4.
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AIM OF STUDY
Neo adjuvant  chemotherapy  in  locally  advanced  breast 
cancer  produces  clinical  and  pathological  changes  that 
frequently  reduces  the  size  of  the  tumor   correlating  with 
response  of  the  distant  metastasis  and  therefore  predicting 
outcome of the breast cancer patients.
1. To  study  the  clinico  pathological  response  of 
primary tumor to the neoadjuvant chemotherapy.
2. To evaluate the improvement in operability 
3. To assess disease free survival.
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SURGICAL ANATOMY OF BREAST
The breast or mammary gland is a modified sweat gland 
situated in the superficial fascia on the anterior chest wall. It is 
rudimentary in male.  In the female,  it  starts enlarging at  and 
after the age of puberty under hormone Influence.
EXTENT5 :
Vertical : 2nd to 6th Rib
Horizontal :  the lateral Margin of the Sternum to Mid Axillary 
line.
Axillary tail of Spence : This  is  the Prolongation from the 
upper outer portion of the deep surface of the mammary gland. 
It is in the direct contact with the main lymph node of the breast. 
(anterior axillary nodes.)
ARCHITECTURE OF THE BREAST
The skin covering the breast presents as erectile conical 
projection called the nipple at the level of the fourth intercostals 
space. The nipple is pierced by 15 to 20 major lactiferous ducts. 
The skin surrounding the base of  the nipple forms a circular 
area  called  the  areola,  rich  in  modified  sebaceous  glands 
appear as nodular elevation during pregnancy and lactation and 
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are called ‘Montgomery’s tubercles.’ The skin of the nipple and 
areola is devoid of hair and there is fat subjacent to it.
The glandular tissue is composed of acini (alveoli) which 
make up lobules aggregation of  which  form the lobes of  the 
gland.  The  gland  consists  of  15  to  20  lobes.  The  lobes  are 
arranged in a radiating fashion and each lobe is drained by a 
separate lactiferous duct.  The dilatation of each duct near its 
termination is called the lactiferous sinus.
Acinar epithelium is cuboidal  in resting phase and  columnar 
during lactation.
The supporting frame work of the gland is the  stroma and 
is partly fibrous and partly fatty. The fibrous stroma forms septa 
known  as  the  suspensory  ligament  of  Asley  cooper  which 
anchor  the gland to the overlying  skin and to the underlying 
pectoral fascia.
BLOOD SUPPLY OF THE BREAST6:
Breast has extensive blood supply. This is derived from,
1. The lateral thoracic, superior thoracic and acromio – 
thoracic, branches of subclavian artery.
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2. The perforating cutaneous branches of the internal 
mammary  artery  to  the  second,  third,  and  fourth 
intercostals spaces.
3. The  lateral  branches  of  the  second,  third,  fourth 
intercostals arteries.
VENOUS DRAINAGE OF THE BREAST :
The  veins  follow the  arteries.  There  is  a  venous  circle 
beneath the areoloar skin called circulous venosum. There is 
also a deeper venous circle at the base of the gland and both 
circles  communicate  each other.  They drain  into  the  internal 
mammary, axillary and posterior intercostals veins.
NERVE SUPPLY OF THE BREAST :
The  breast  is  supplied  by  the  anterior  and  lateral 
cutaneous  branches  of  the  second  to  the  sixth  nerves.  The 
nerves convey sensory fibres to the skin and autonomic fibres 
to smooth muscles and blood vessels.
LYMPHATIC DRAINAGE OF THE BREAST7 :
The breast is drained by two sets of lymphatics.
1. Lymphatics of the skin of the breast.
2. Lymphatics of the parenchyma of the breast.
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LYMPHATICS OF THE SKIN OF THE BREAST :
The lympahtics  drains the Integuments over the breast, 
but not the nipple and areola. These lymphatics passes radially 
and  end  in  the  surrounding  lymph  nodes,  axillary, 
supraclavicular, and internal mammary nodes.
The  lymphatics  of  the  skin  communicate  across  the 
midline and a unilateral disease may become bilateral by this 
route.
LYMPHATICS OF THE PARENCHYMA OF THE BREAST :
These lympatics drains the parenchyma of the breast and 
the nipple and areola.
The subareolar lymph plexus of sapey is a collection of 
large lymph vessels  communicate  with  the lymphatics  of  the 
breast tissue. It is not a collecting zone for the breast lymph.
The axillary nodes receive about 75% of lymph, draining 
the  breast  tissue.  Among  the  axillary  nodes  most  of  the 
lymphatics are in the  anterior group (closely related to axillary 
tail) and partly in the posterior and apical group. From there, 
they drains to the central and lateral group and through them to 
the apical group ( High axillary lymph nodes.)
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To  standardize  the  extent  of  axillary  dissection,  the  axillary 
space of lymph nodes is arbitrarily divided into three levels.
LEVEL I NODES :
Lateral  to  lateral  border  of  Pectoralis  Minor  muscle 
including external mammary, scapular and central axillary group 
of nodes.
LEVEL II NODES :
It lies under the pectoralis minor muscle, including some 
of the nodes of central axillary group.
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ANATOMY OF AXILLARY LYMPH NODES AND LYMPH VESSELS
SCHEMATIC REPRESENTATION OF ROUTES  OF LYMPHATIC 
DRAINAGE
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LEVEL III NODES :
It  lies  medial  to  the  medial  border  of  pectrolis  minor 
muscle including apical lymph nodes.
SITUATION OF THE AXILLARY NODES
ANTERIOR SET :
Situated along the lateral thoracic vein under the anterior 
axillary fold lying mainly on the third rib in close contract with 
the axillary tail of spence.
POSTERIOR SET :
These lymph nodes lie along the posterior axillary fold in 
relation to the subscapular vessels.
LATERAL SET :
These  lymphnodes  lie  along  the  upper  part  of  the 
humerus in relation to the axillary vein.
CENTRAL SET :
Situated  in  the  fat  of  the  upper  part  of  axilla.  The 
intercosto brachial nerve plexus outwards among these nodes.
APICAL SET :
Also called the ‘infraclavicular set’ bounded below by the 
first Intercostal space, behind by the axillary vein, in front by the 
costo coracoid membrane.
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1. A  single  lymph  trunk  leaves  the  apical  group  on 
each  side  of  the  subclavian  trunk  and  enters  at  the 
junction of the internal jugular and subclavian vein (or) it 
may join the thoracic duct on the left side of neck.
2. About 20% of the lymph from the breast drained into 
the internal mammary nodes.
3. About 4% of the lymph from the breast drains into 
posterior  intercostals  Nodes  along  the  perforating 
branches of the internal mammary artery and along the 
lateral perforating branches of the intercostals vessels.
4. Lymphatics from the lower and inner quadrant of the 
breast may communicate with the sub diaphragmatic and 
sub  peritoneal  lymph  vessels  after  crossing  the  costal 
margin and then piercing the abdominal wall through the 
upper part of the linea alba.
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PATHOLOGY OF BREAST CARCINOMA
Because  of  more  complex  structure,  the  greater  volume 
and it’s extreme sensitivity for endocrine influences the female 
breast is more prone for various pathological diseases than the 
rudimentary male breast.
Breast malignancy are basically classified into two types
Non invasive
Invasive  
NON-INVASIVE (IN SITU) CARCINOMA :
(A) INTRADUCTAL CA (DCIS) 8:
With the advent of mammography,  it  now constitutes 22-
80% of carcinoma’s. it is defined as malignant population of cells 
that lack the capacity too invade the basement membrane and 
incapable  of  distant  metastasis.  The  Cells  are  large  and 
pleomorphic  vacuolated  macro  phages  contains  hemosiderin 
pigments  represents  the  comedo  plugs.  Calcification  may  be 
seen.
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-DCIS
-LCIS
There are five subtypes9, They are :
a. Comedo carcinoma
b. Solid
c. Cribriform
d. Papillary
e. Micropapillary
Among these, comedo carcinoma is more malignant.
COMEDO CARCINOMA :
Usual findings are :
1. Variable cell yield
2. Neoplatic cells in irregular aggregates and singly.
3. Large,  pleomorphic  cells  showing  obvious  malignant 
features.
4. Necrotic  debris,  lymphocytes  and  vacuolated 
macrophages.
PAPILLARY TYPE10:
The smear has abundant papillary aggregates with central 
fibrovascular core. Columnar cells in rows, palisades and single. 
Bare  nuclei  of  benign  type  is  absent.  Variable  nuclear 
enlargement  pleomorphism  and  atypia  seen.  Necrotic  debris 
present. 
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CRIBRIFORM TYPE:
Epithelial  cells  relatively  cohesive  forming  large  mono 
layered sheets are seen. Mild epithelial atypia and debris is seen. 
Macrophages often with hemosiderin pigment is present.
(B) LOBULAR CA IN SITU (LCIS) :
There is  proliferation  of  loosely  cohesive  cells  in  one or 
more terminal ducts / acini. It is frequently multifocal and bilateral, 
the  lesion  is  a  marker  for  invasive  carcinoma.It  is  difficult  to 
define  cytological  criteria  for  this  diagnosis  in  FNA  smear. 
Intracytoplasmic  neolumina  is  the  most  useful  clue  to  the 
cytological diagnosis (Salhany and Page)11.
II INVASIVE CARCINOMA :
Features in breast needle aspirates of malignant  lesions 
are
1. Loss of cell adhesion
2. Cellularity high
3. Lack of stripped nuclei
4. Increased cell size
5. Pleomorphism
6. Variable  nuclear  chromatin  often  with  prominent 
nucleoli occasionally a lymphocyte response.
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FNAC PICTURE OF INVASIVE DUCTAL CARCINOMA
           
FNAC PICTURE OF INVASIVE LOBULAR CARCINOMA
21
(A) INVASIVE DUCTAL CARCINOMA :
Common type. Incidence 65-80% of all mammary cancers. 
There may be nipple retraction, dimpling of skin, fixity to muscle 
chest  wall.  Histologically,  cells  lining the duct  are  disposed in 
cords, solid cell nests tubular glands, anastamosing masses.
Criteria for diagnosis:
1. High cell yield
2. A dingle population of atypical epithelial cells
3. Irregular angulated clusters of atypical cells
4. Reduced cohesiveness of epithelial cells
5. Nuclear enlargement and irregularity
6. Single cells with intact cytoplasm
7. Absence of single nare nuclei
8. Necrosis, important if present
A scirrhous cancer may yield very few cells or no cells at 
all. Nuclei irregular shape and irregular contours is diagnostic of 
malignancy.  However  the  cell  population  can  be  quite 
monomorphous and nuclear abnormalities may be suitable12.
In poorly differentiated carcinoma dissociation of cells may 
be  total  and  smear  may resemble  large  cell  lymphoma.  Cells 
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usually  have  well  defined  cyto  plasm,  but  infiltrating  lobular 
carcinoma is an exception.
(B) INVASIVE LOBULAR CARCINOMA :
Peculiar feature is bilateral and multicentiric. Histologically, 
it consists of stands of infiltrating tumour cells, lossely disposed 
throughout the fibrous matrix. It have an abundant desmoplastic 
storma. The cells are seen in small groups and single file. The 
cells  have  often  lost  their  cytoplasm  and  often  show nuclear 
moulding.
The other findings are : 
Poor cell yield. 
Cytoplasm scanty, and indistinct.
Small dark nuclei with Irregularity in shape.
(C) MEDULLARY CARCINOMA :
Incidence 1-5%. It has soft empty feel to the needle. It often 
bleeds easily. Do not have striking desmoplasia The cytology is 
quite similar to comedocarcinoma. The smear is highly cellular. 
Irregular  cell  aggregates  and  single  cells  with  lymphocytic 
infiltration  is  seen.  Nuclei  are  large  and  pleomorphic. 
Histologically,  solid  syncytium  like  sheets  of  large  cells  with 
lymphocytic infiltration is present.
23
(D) COLLOID OR MUCINOUS CARCINOMA :
Occurs in old woman,  slow growing,  Macroscopically are 
well circumscribed with soft pale surfaces. Histologically , large 
lakes  of  amorphous  mucin  with  scattered  neoplastic  cells  are 
present.a small  amount  of  fibrous stroma is  also present.  The 
cells are rather uniform and exhibit mild atypia. These tumor has 
better  prognosis  when  compared  to  that  of  invasive  ductal 
carcinoma.
(E) TUBULAR CARCINOMA13 : 
Macroscopically they are poorly circumscribed with hard in 
consistency  and  are  small  in  size.  Microscpically,  it  shows 
moderately cellular smears. Cells are predominantly in cohesive 
clusters. Epithelial with an angular shape and tubular pattern is 
present single bare nuclei are often present. An associated intra 
ductal carcinoma of cribriform type is seen in two third of cases. 
They have the excellent prognosis. 
(F) PAGET’S DISEASE OF NIPPLE
There  is  invariably  underlying  ductal  carcinoma  in  situ. 
Histologic hallmark is involvement of epidermis by malignant cells 
Background  shows  ketatin,  squamous  cells  and  inflammatory 
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cells.  Abundant  pale  cytoplasm  with  distinct  borders  is  seen. 
Nuclei show features of malignancy.
(G) INFLAMMATORY CARCINOMA :
There  is  thickening  and  erythema  of  the  skin  due  to 
extensive intralymphatic spread of tumour causing lymph stasis 
and  edema.  The  cytological  pattern  is  similar  to  that  of  the 
common  carcinoma   Inflammatory  cells  are  not  seen.  It  is  a 
rapidly progressive tumor and high propensity for early metastatic 
spread.
(H) SARCOMA14 : 
Smear from a tumour fragments of highly cellular stromal 
tissue  of  spindle  cells  which  may  show  nuclear  atypia  and 
pleomorphism. There is variable number of sheets of epithelial 
cells. However definitive diagnosis is by biopsy.  In angiosarcoma 
aspiration yields plenty of blood and tumour cells may be few in 
numbers.  Most  cells  are  in  syncitial  clusters  but  some  are 
single15.
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RISK FACTORS FOR DEVELOPMENT 
OF BREAST CARCINOMA 
1. Genetic and familial factors.
2. Hormonal factors.
3. Benign Breast disease.
4. Dietary and environmental influences.
1. GENETIC FACTORS16 :
Only about 10% of breast cancers of human breast cancer 
can  be  linked  directly  to  germ line  mutations.  The  first  to  be 
identified was germ line mutations in tumour suppressor gene P 
53.
Another Putative tumour suppressor gene – BRCA gene – 
1 has been identified at the chromosomal locus 17q21 ; this gene 
encodes  a  zinc  finger  protein  and  the  product  therefore  may 
function ad transcription factor.  Women who inherit  the mutant 
alleles of this gene from either parent have an approximately 85 
to 90% life time chance of developing breast cancer. Men who 
carry  this  mutant  alleles  have  increased incidence  of  prostate 
cancer but not usually the breast cancer.
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A  third  gene  BRCA  –  2,  which  has  been  localized  to 
chromosome 11, is associated with increased incidence of breast 
cancer in Men and women.
Even  more  important  than  the  role  these  genes  play  in 
inherited forms of breast cancer susceptibility, may be their role 
in sporadic breast cancer. For example P53 gene in present in 
approximately 40 % of human breast cancer in acquired defect. 
IN small series of sporadic breast cancer, decreased expression 
of  BRCA  -  1  mRNA  occurs.  An  abnormal  cellular  location  of 
BRCA – 1 protein has also been found in some breast cancers.
2. FAMILIAL FACTORS :
A woman  with  a  family  history  of  breast  cancer  has  an 
increased risk of developing breast cancer in her life time. The 
risk  varies  with  the  degree  of  relation  of  the  patient,  whether 
cancer  developed  in  premenopausal  (or)  post  menopausal 
period, unilateral (or) bilateral breast cancer and others.
The life  time risk for  a woman with  affected mother  (or) 
sister in as follows :
. Unilateral and post menopausal - 15-20%
. Unilateral & premenopausal - 25%
. Bilateral & Postmenopausal - 35-40%
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. Bilateral & Premenopausal - 50-65%
Risk  increased  when  more  than  one  relative  members 
involved by breast carcinoma.
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3. HORMONAL FACTORS :
Breast  Cancer  is  related  to  hormones  and  reproductive 
factors. The principle hormone is estrogen. Prolonged exposure 
of  breast  tissue  to  unopposed  estrogen  action  increases  the 
incidence of breast cancer.
. Age at Menarche
. Age at Menopause
. Parity and age at First child birth.
. External use of hormones.
. Oophorectomy.
HORMONAL FACTOR IMPLICATIONS :
Menarche : 20% decrease in risk for each year delay.
Menopause : Before  45  years,  the  risk  is  half 
compared to                        menopause after 55 years.
Parity : Nulliparous risk is twice more than 
parous women.
Pregnancy : After  30  years,  the  risk  is  2  to  5  times 
more compared to pregnancy and child birth at 18 / 17 years.
Abortions : No protection.
Oophorectomy : Before  50  years  decreases  the  risk  of 
development of breast cancer.
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ORAL CONTRACEPTIVES :
The  most  valuable  analysis  of  increased  risk  of  breast 
cancer, with oral contraceptive suggest that there is little, if any 
increased risk usually after prolonged use of Oral contraceptives 
for more than seven years.
4. DIETARY FACTORS :
The role of diet in breast Carcinoma is controversial. While 
there is associative links between total caloric intake and breast 
cancer  risk,  the  strongest  link  is  with  high  dietary  fat  intake. 
However  within  the  range  of  delivery  fat  intake  common  in 
western countries, there is no convincing evidence that variations 
in  dietary  fat  alter  breast  cancer  risk.  There  is  increased  risk 
associated  with  moderate  alcohol  intake,  increased  risk 
associated with cigar smoking.
5. OBESITY :
Increased risk attributed to the synthesis of Oestrogens in 
fat deposits, especially in postmenopausal women.
6. RADIATION :
May be a risk factor in younger women,. Women who have 
exposed before the age of 30, the high dose radiation in the form 
of multiple fluroscopies (200-300 Gray) or treatment for Hodgkin’s 
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lymphoma (<3600 Gray) may be substantially increased risk of 
breast cancer, whereas exposure after the age of 30, appears to 
have minimal iatrogenic effect on the breast.
7. BENIGN BREAST DISEASE :
Fibro  cystic  diseases  with  atypical  hyperplasia  are 
associated  with  increased  risk  of  about  4.4  times  the  risk  of 
developing breast cancer.
*  Carcinoma  of  contralateral  breast  and  endometrium  are 
associated with increased risk of developing Breast cancer.
RISK FACTORS FOR BREAST CANCER
Major Minor
1. Gender female >male 1. Early menarche
2. Age 2. Late menopause
3. Family history 3. Obesity
4. Personal history of contra 4. History of radiation
lateral breast cancer.
5. Benign breast disease 5. Late child birth
with epithelial atypia.
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LOCALLY ADVANCED BREAST 
CARCINOMA-AN OVERVIEW
Locally advanced Breast Carcinoma is a term that refers 
to  most  advanced  stage  non  metastatic  breast  tumors  and 
encompass  wide  variety  of  clinical  scenarios.  Despite  its 
decreasing  frequency  over  the  past  several  decades  locally 
advanced  breast  carcinomas  remains  an  important  and 
challenging problem in clinical practice. M.D Anderson Cancer 
Center  defines  Locally  advanced  Breast  Carcinoma  as  any 
advanced primary  tumors   that  is  greater  than  5cms or  that 
involves the skin or chest wall, advanced nodal stages that is 
patients  with  fixed  axillary  lymphnodes  or  ipsilateral 
supraclavicular,  infraclavicular,  or  internal  mammary  nodal 
involvement  and  inflammatory  carcinomas..  In  TNM  staging 
classification, LABC is represented by stage III A (To N2, T1/T2-
N2,  T3N1/2) IIIB (74No-2) and IIIC disease (Any T,  N3)17.  IBC 
constitutes T4d primary tumor designation and therefore stage 
III B disease. 
32
TNM Staging System for Breast Cancer presented in the 
fifth edition of the AJCC Cancer Staging Manual,
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
    Tis (DCIS) Ductal carcinoma in situ
    Tis (LCIS) Lobular carcinoma in situ
    Tis (Paget) Paget’s disease of the nipple with no tumor
Note:  Paget’s  disease  associated  with  a  tumor  is 
classified according to the size of the tumor.
     T1 Tumor 2 cm in greatest dimension
    T1mic Microinvasion 0.1 cm in greatest dimension
    T1a Tumor > 0.1 cm but not > 0.5 cm in greatest dimension
    T1b Tumor > 0.5 cm but not > 1 cm in greatest dimension
    T1c Tumor > 1 cm but not > 2 cm in greatest dimension
    T2 Tumor > 2 cm but not > 5 cm in greatest dimension
T3 Tumor > 5 cm in greatest dimension
T4 Tumor of any size with direct extension to
(a) chest wall or
(b) skin, only as described below
    T4a Extension to chest wall, not including pectoralis muscle
    T4b Edema (including peau d’orange) or ulceration of the 
skin of the breast, or satellite skin nodules confined to 
the same breast
    T4c Both T4a and T4b
    T4d Inflammatory carcinoma
Regional  lymph 
nodes (N)
NX Regional  lymph  nodes  cannot  be  assessed  (eg, 
previously removed)
N0 No regional lymph node metastasis
N1 Metastasis  in  movable  ipsilateral  axillary  lymph 
node(s)
N2 Metastases in ipsilateral axillary lymph nodes fixed or 
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matted,  or  in  clinically  apparent*  ipsilateral  internal 
mammary  nodes  in  the  absence  of  clinically  evident 
axillary lymph node metastasis
    N2a Metastasis in ipsilateral axillary lymph nodes fixed to 
one another (matted) or to other structures
    N2b Metastasis  only  in  clinically  apparent*  ipsilateral 
internal  mammary  nodes  and  in  the  absence  of 
clinically evident axillary lymph node metastasis
N3 Metastasis in ipsilateral infraclavicular lymph node(s), 
or in clinically apparent* ipsilateral internal mammary 
lymph node(s) and in the presence of clinically evident 
axillary  lymph  node  metastasis;  or  metastasis  in 
ipsilateral  supraclavicular  lymph  node(s)  with  or 
without  axillary  or  internal  mammary  lymph  node 
involvement
    N3a Metastasis in ipsilateral infraclavicular lymph node(s) 
and axillary lymph node(s)
    N3b Metastasis  in  ipsilateral  internal  mammary  lymph 
node(s) and axillary lymph node(s)
    N3c Metastasis in ipsilateral supraclavicular lymph node(s)
Regional  lymph 
nodes (pN)
pNX Regional  lymph  nodes  cannot  be  assessed  (eg, 
previously  removed  or  not  removed  for  pathologic 
study)
pN0 No regional lymph node metastasis histologically, no 
additional examination for isolated tumor cells
    pN0(i-) No  regional  lymph  node  metastasis  histologically, 
negative IHC
    pN0(i+) No  regional  lymph  node  metastasis  histologically, 
positive IHC, no IHC cluster > 0.2 mm
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    pN0(mol-) No  regional  lymph  node  metastasis  histologically, 
negative molecular findings (RT-PCR)
    pN0(mol+) No  regional  lymph  node  metastasis  histologically, 
positive molecular findings (RT-PCR)
    pN1mi Micrometastasis (> 0.2 mm, none > 2.0 mm)
    pN1 Metastasis in one to three axillary lymph nodes and/or 
in internal  mammary nodes with microscopic disease 
detected  by  sentinel  lymph  node  dissection  but  not 
clinically apparent
    pN1a Metastasis in one to three axillary lymph nodes
    pN1b Metastasis  in  internal  mammary  nodes  with 
microscopic disease detected by sentinel  lymph node 
dissection but not clinically apparent
    pN1c Metastasis in one to three axillary lymph nodes and in 
internal  mammary  lymph  nodes  with  microscopic 
disease detected by sentinel lymph node dissection but 
not clinically apparent ,||
pN2 Metastasis in four to nine axillary lymph nodes, or in 
clinically apparent* internal mammary lymph nodes in 
the absence of axillary lymph node metastasis
    pN2a Metastasis in four to nine axillary lymph nodes (at least 
one tumor deposit > 2.0 mm)
    pN2b Metastasis  in  clinically  apparent*  internal  mammary 
lymph  nodes  in  the  absence  of  axillary  lymph  node 
metastasis
 TNM Stage Grouping for Breast Cancer 
Stage Grouping 
0 Tis N0 M0
I T1* N0 M0
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IIA T0 N1 M0
T1* N1 M0
T2 N0 M0
IIB T2 N1 M0
T3 N0 M0
IIIA T0 N2 M0
T1* N2 M0
T2 N2 M0
T3 N1 M0
T3 N2 M0
IIIB T4 N0 M0
T4 N1 M0
T4 N2 M0
IIIC Any T N3 M0
IV Any T Any N M1
NOTE. Adapted with permission of the American Joint Committee on 
Cancer (AJCC), Chicago, IL. The original source for this material is 
the AJCC Cancer Staging Manual, Sixth Edition (2002) published by 
Springer-Verlag New York, www.springer-ny.com.
Inflammatory Breast Carcinoma 
It’s  a  distinct  clinical  subtype  of  LABC.  Primary  IBC is 
relatively rare accounting for 0.5-2% of invasive Breast Cancer 
common in pre and perimenopausal women and rare in men. 
Pregnancy and lactation do no predispose to the development 
of IBC18. It is a rapidly progressive tumor and high propensity for 
early metastatic spread.  Median survival of woman with IBC 
was significantly worse than for women with non inflammatory 
LABC (2.9 versus 6.4 years)19.  Secondary inflammatory breast 
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cancers  develop  from  neglected  locally  advanced  Breast 
Cancers  but  should  be  distinguished  as  these  may  follow a 
more indolent  course and can be treated as other LABC20
DIAGNOSIS AND STAGING
Clinical  presentations  of  most  of  the  Locally  advanced 
Breast Carcinoma are
• Large tumors (>5cm)
• Extreme regional lymph node involvement
• Direct involvement of skin or underlying chest wall
• Tumors  that  are  inoperable  but  without  distant 
metastasis  (including  involvement  of  supra  elevation 
lymph nodes)
• Inflammatory Breast Cancer)
Diagnosis of  IBC is  a clinical  one and typically  present 
with pain and a rapidly progressing, warm, tender, firm enlarged 
breast. Diffuse  brawny induration of the skin of the breast with 
a  peau-de-orange  appearance  usually  without  underlying 
palpable  mass.  The  malignant  cells  forms  tumor  emboli 
invading dermal  lymphatics  results  in  blockage of  lymphatics 
which are responsible for local signs and symptoms and distant 
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spread21.   Primary IBC is not  a specific histologic subtype of 
breast cancer but most often of the ductal type.
A  needle  biopsy  usually  establishes  the  histologic 
diagnosis  of  LABC.   A  full  thickness  skin  biopsy  is  often 
obtained if IBC is suspected, as the hall mark of this disease is 
dermal  lymphatic invasion.  Once diagnosis is established, the 
following staging studies are generally recommended22.
1. Complete history with physical examination
2. Bilateral mammography
3. Complete basic blood investigation
4. Chest radiography / CT, ultrasound
5. Pathology review and determination of ER, PR and 
HER –
2 status
PROGNOSTIC FACTORS
Prognostic factors for locally advanced tumors are similar 
to the prognostic factors for earlier stage breast cancer includes 
age,  menopausal  status,  tumor  stage,  histological  grade,  ER 
status and response to therapy 23. Lymph node status and tumor 
size having the strongest effect on survival.  The prognosis for 
patient with out lymph node metastasis is better than for those 
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patients with lymph node involvement and greater the number 
or  higher  nodal  stage predict  poor  survival  24.  Breast  tumors 
measuring  <5cm,  5-10cm,  >10cm  associated  with  5  year 
survival rates of 65%, 36% & 16% indicating the size of tumor 
also affects the survival rates25.  Role of hormone receptor in 
LABC is less clear but studies found that ER and PR negativity 
was  associated  with  shorter  overall  survival  times  26 and 
hormone receptor positively is associated with longer survival 
time.
With  above  indicated  prognostic  factors,  patients  with 
axillary Lymphnode negative classified in 3 groups.
Low risk Moderate risk High risk
Tumor < 1 CMs Turmor 1 – 2 cms    Tumor more than 2 
cms.
Histology tubular, colloid    Histology  -  Comedo 
form
Papillary, less than 2 cms,
ER / PR positive ER / PR positive ER / PR Negative
Nuclear Grade I Nuclear grade II Nuclear  Grade-II, 
III
Age More than 35 years Age-Less 
than 35 yrs
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DNA Diploidy         Over  expression 
Cathesin ‘D’
Low ‘S’ phase fraction. High ‘S’ phase fraction.
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Other  variables  investigated  as  possible  prognostic 
markers  in  locally  advanced  breast  cancer  includes  HER2, 
P53,nuclear grade. P53 positivity was associated with shorter 
overall  survival  rate.  .Her2  and  nuclear  grade  have  not 
consistently emerged as independent predictors of survival in 
multivariate  analysis.  Thymidine   labeling  index  was  a 
prognostic factor with a high TL1 predicting poorer survival 27
Less common prognostic factors are
A. Proliferative indices like  ki-67, PCNA/Cyclin, MIB-1
B. Topoisomerase II
C. Histone H3
D. Transforming growth factors (a,b)
E. Epidermal growth factor
F. Oncogene products (c-erb2,c-myc,ras, rb, Bcl2)
G. Invasion related proteins like Cathepsin-D, Laminin, 
Stromelysin, UPA/PA-1
H. Angiogenesis factors
I. PS2
J. NM- 23
K. Heat shock proteins
L. MDR -1 protein ( multi drug resistant protein)
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EVOLUTION OF THERAPY
According  to  National  Cancer  Institute’  s  surveillance 
Epidemiology and End Result program (SEER)  the 3- and 5- 
year  survival  rates  for  woman  with  stage  III  breast  cancer 
patients are 70% and 55% respectively and median survival is 
4.9  years.  Treatment  for  locally  advanced  breast  carcinoma 
requires combination of  systemic  chemotherapy,  surgery  and 
radiotherapy  to  optimize  the  chance  of  cure.   The  earlier 
therapy  for  locally  advanced  carcinoma  was  radical 
mastectomy.   However  patient  with  chest  wall  fixation,  skin 
edema, ulceration, presence of satellite nodules, inflammatory 
Breast  carcinomas,  matted  (or)  fixed  lymph  nodes, 
supraclavicular lymph nodes, or  ipsilateral arm edema were all 
found  to  develop  recurrences  and  these  grave  signs  were 
considered as markers of  inoperable disease28 Patients were 
treated  with  primary  radiotherapy  also  had  risk  of  disease 
recurrence and death as well as the complication of chest wall 
fibrosis, Brachial plexopathy, lymphedema, skin ulceration and 
skin necrosis  29 Neo adjuvant chemotherapy was pioneered in 
the setting of  locally advanced carcinoma in 1970 and major 
clinical responses to induction chemotherapy were noted in the 
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majority of patients and some were found to have no invasive 
tumour remaining within the breast or regional nodes at the time 
of surgery. 
These data  led  to  the  hypothesis  that  the  early  locoregional 
response  to  neoadjuvant  chemotherapy  was  a  marker  for 
response in distant occult micrometastases and that it could be 
used  as  a  surrogate  for  the  overall  efficacy  of  the 
chemotherapy.  Recently  response  to  chemotherapy  has 
allowed  breast  conserving  therapy  to  become  possible  for 
woman who would otherwise have been eligible for mastectomy 
only  and  has  substantially  improved  the  prognosis  of  LABC 
patients.
The advantages of preoperative chemotherapy in LABC are
1. Chemotherapy administered prior of tumor removal 
is  more  biologically  favorable  than  post  operative 
administration 30.
2. Can reduce  the  size  of  the  primary  tumor  render 
inoperable  tumors  resectable  and  sometimes   even 
allowing for breast conserving surgery.
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3. Permit a direct in vivo measure of the sensitivity of 
the  tumor  cells  to  the  chemotherapeutic  drug   in  that 
regimen, 
4. Early identification of any resistance can prompt the 
change to a potentially more effective regimen31
5. Enable  drug  delivery  through  an  intact  tumor 
vasculature.
On the other hand the disadvantages are
1. Fewer than 5% of patients with LABC progress while 
undergoing  neoadjuvant  chemotherapy  hence  local 
treatment will be delayed.
2. Development of early drug resistance
3. May  possibly  increase  the  risk  for  surgical  and  radiation 
related complication but not proven 32
In  practice  advantages  of  induction  chemotherapy 
exceeds the disadvantages and this approach has become the 
standard  treatment  of  care  for  woman  with  stage  III  breast 
cancer 
CHOICE OF CHEMOTHERAPY REGIMEN 
Most  treatment  guidelines  recommend  an  initial 
Anthracyclin  based  regimen33  Similar  to  the  situation  with 
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standard  adjuvant  chemotherapy,  Anthracyclin  and 
Cyclophosphamide  (AC)  most  commonly  with  Flurouracil 
(FAC)regimen  is  used  Other  effective  Anthracyclin  based 
regimen includes Doxorubicin followed by CMF and intensive 
multidrug regimen. The recommended dose and schedule are 
the same as those used in the adjuvant therapy. Taxanes adds 
substantial  efficacy  to  adjuvant  chemotherapy  and  they  are 
increasingly used for patients with node positive breast cancer. 
Trials  are  addressing  the  issues  of  induction  regimens  (i.e.) 
sequential  Anthracyclin  based  chemotherapy  followed  by 
Taxanes  are  associated  with  twofold  higher  pathological 
complete response with better disease free survival and over all 
survival34.  Taxanes  are  incorporated  either  as  a  cross  over 
regimen  follow  (or)  preceding   Four  cycles  of  Anthracyclin 
based  regimen  or  as  a  component  of  an  established 
Anthracyclin  based regimen substituting  for  an  existing  older 
drug (eg Doxetaxal instead of flurouracil).
ROLE OF TRASTUZUMAB.
Trastuzumab  is  a  monoclonal  antibody  that  binds  to  a 
specific epitope of the HER-2/NEU protein. Approximately 20% 
of tumor breast cancers have amplified or over expressed HER-
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2/neu (c-erB-2)  a gene which encodes a cell  surface growth 
factor receptor. Multiple doses can be given safety both alone 
and in combination with other chemotherapeutic agents. 
Initial  reports  about  Neoadjuvant  Trastuzumab  are 
encouraging but  still  be  considered investigational  at  present 
since data on long term outcome and safety are lacking 35
HIGH DOSE THERAPY WITH HEMATOPOIETIC STEM CELL 
SUPPORT
Main  reason  for  treatment  failure  is  lack  of  systemic 
control  a  fact  that  has  led  to  the  development  of  high  dose 
chemotherapy regimen with autologous stem cell support and is 
indicated  in  progressive  disease  while  receiving  neoadjuvant 
chemotherapy  and  IBC.   In  general,  higher  objective  and 
pathologic response rates have been obtained as a component 
of combined modality therapy, but there have been no dramatic 
improvements in either disease free survival or over all survival 
36 and  more  over  this  approach  is  associated  with  markedly 
increased   toxicity  and  worse  quality  of  life  compared  to 
standard dose chemotherapy
DURATION OF NEOADJUVANT CHEMOTHERAPY
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Optimal duration of induction chemotherapy has not been 
established in randomized controlled trials.  Based on various 
results,  2003  consensus  conference  on  neoadjuvant 
chemotherapy  for  breast  cancer  recommended  the  following 
approach to induction therapy 37.
• Four cycles of an anthracyclin based regimen or a 
taxanes followed by reassessment of response.
• If  there  has  been  a  complete  or  nearly  complete 
clinical  response  to  induction  therapy  definite  local 
treatment is appropriate.
• Patients with a lesser response could be considered 
for additional cycles of a non cross resistant drugs.
• Eight  total  cycles  of   adjuvant  therapy  are 
recommended.  They may all administered preoperatively 
(or) split between induction and postoperative therapy.
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PRIMARY TUMOUR BEFORE NEO ADJUVANT CHEMO THERAPHY
WITH ELEVATED AND RETRACTED NIPPLE
      
REGRESSED PRIMARY TUMOUR AFTER NEO ADJUVANT CHEMO 
THERAPHY 
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• In the absence of progressive disease atleast two or 
preferably four cycles should be given before concluding 
patients as Non responders.
RESPONSE TO NEOADJUVANT THERAPY
Clinical measurements of breast masses are often used to 
assess the response to neoadjuvant chemotherapy. Universally 
accepted  criteria  for  response  to  Neoadjuvant  chemotherapy 
are classified by the world health organizations / international 
union against cancer (WHO/UICC)  that have been used for 20 
year defines 
A  clinical  complete  response  (CCR)  as  complete 
disappearance of all clinically detectable disease in the breast 
or regional lymph node (41). A partial response (PR) requires a 
>50%  reduction  in  the  sum  of  the  product  of  two  largest 
dimensions of measurable tumor. <50% reduction in the sum of 
the  product  of  two  largest  dimensions  of  measurable  tumor 
Minor responders    Non responders(NR) as there no change in 
clinical status.  Progressive disease includes >25% increase in 
sum of product of two largest perpendicular dimension of the 
tumor38 
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Same clinician should perform longitudinal assessment of 
chemotherapy  response  although  mammography  and 
ultrasound  are  of   limited  value  for  monitoring  response  to 
neoadjuvant therapy. None of 
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FNAC PICTURE OF PRIMARY TUMOUR BEFORE NEO ADJUVANT 
CHEMO THERAPHY
HISTO PATHOLOGY PICTURE OF PRIMARY TUMOUR AFTER 
NEO ADJUVANT CHEMO THERAPHY SHOWING CYTOPLASMIC 
VACOULISATION 
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the additional imaging modality such as MRI, Helical CT, even 
PET scans are routinely used for response assessment39
Based  on  histological  response  to  neoadjuvant 
chemotherapy  such  as  cytoplasmic  vacuolization,  change  in 
mitosis, tumour sclerosis in the primary tumor and the presence 
of  nodal  fibrosis  mucin  pools  or  large  aggregates  of  foamy 
histiocytes  in  the  lymph  node(1b),  Pathological  complete 
response was characterized as when there is no evidence of 
residual invasive tumor in the Breast or axillary lymph nodes. 
Partial  pathological  response  is  either  residual  non  invasive 
tumor (or) microscopic foci of tumor cells of more or less than 
1cm3.  Pathological lack of response is confirmed by comparing 
tumor size measurement of surgical specimen with clinical size 
measurements 40
MOLECULAR PREDICTORS OF RESPONSE 
Many investigations studied about markers that  predict 
response to chemotherapy for patient treated with anthracyclin 
based  induction  chemotherapy,  high  nuclear  grade,  high 
proliferative index (K167) and co expression of HER2/neu and 
topoisomerase II have been associated with greater response 
rate 41.  Conversely  mutation of the P53 gene is associated with 
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a lower response rate to chemotherapy42  and tumors with low 
level  of  HER-2  expressions  are  more  likely  to  respond  to 
concomitant  paclitaxal  therapy43 Since  response  to 
chemotherapy  is  an  important  predictor  of  survival,  studies 
about predictors are too preliminary at this point to be used in 
clinical setting since sufficient data are lacking.
NEOADJUVANT HORMONE THERAPY  : NAHT
It  is  an  acceptable  option  for  selected  patients  with 
Estrogen receptor positive Breast cancer although the likelihood 
of complete pathologic response appears to be lower than with 
systemic therapy 44
Tamoxifen :
Neoadjuvant tamoxifen decreases overall tumor volume in 
approximately  one  half  of  LABC  and  pathological  complete 
response appears  to  be low about   approximately  5% Since 
response tend to occur gradually, treatment for 3-6 months is 
necessary in the absence of progression before concluding that 
disease is unresponsive 
Aromatase Inhibitors
With Aromatase Inhibitors the medium reduction in tumor 
volume  over 12 weeks was 70 to 80%  in ER positive locally 
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advanced breast Cancer patients45 and in woman whose tumor 
expresses  HER  2/neu  and  erbB-1  may  preferentially  benefit 
from NAHT with Aromatase Inhibitors compared to Tamoxifen.
NAHT is an effective approach for woman with LABC but 
may  be  reserved  for  elderly  woman  with  impaired  organ 
function,  patient  who  are  unwilling  to  accept  chemotherapy 
related toxicity or those with poor performance status or who 
are felt to have unacceptably high surgical risk 
INDUCTION CHEMORADIATION
Concurrent radiation therapy and chemotherapy has only 
rarely been applied to patients with LABC because of concerns 
about  radiosensization  with  anthracyclins.   The  efficacy  has 
prompted a revolution of the benefits of initial chemotherapy 46 
As  long  term  results  are  not  yet  available,  this  treatment 
approach is still under study.
LOCAL THERAPY
Following  induction  chemotherapy,  the  options  for  local 
therapy  are  surgery(Mastectomy)  or  RT  or  both.  In  general, 
assessment  of  tumor  response after  induction  chemotherapy 
usually  drives  loco  regional  management  recommendations. 
The risk of locoregional recurrence in woman with LABC who 
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are treated with surgery or RT alone is approximately 30 to 50 
present  and  the  most  studies  that  have  compared  primary 
radiation  therapy  with  primary  surgical  therapy  have  shown 
equivalent outcome  47  But postoperative RT had significantly 
lower  rate  of  10  year  loco  regional  recurrence  and  cause 
specific  survival  was  also  significantly  better  for  these  with 
Stage III B disease, Clinical T4 tumors, or > 4 positive nodes 48 
Indications for locoregional RT is controversial but in selective 
cases.
Indications for post op RT includes:
1. tumour size more than 5cms diameter
2. intensive pectoral muscle involvement
3. positive surgical margins
4. >4 positive axillary lymph nodes
5. gross extracapsular tumor extension.
Hence  local  control  rates  appear  higher  when  both 
surgery and RT are included in the treatment strategy even for 
woman  who  have  partial  clinical  response  to  neoadjuvant 
chemotherapy.
BREAST CONSERVING THERAPY AFTER NEOADJUVANT 
CHEMOTHERAPY(BCT) :
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50-90% of woman with LABC can be successfully treated 
with  Breast  Conserving  surgical  Therapy  (BCT)  after 
Neoadjuvant chemotherapy but not appropriate for all  women 
even if they appear to have achieved major clinical response. 
Recommended eligible criteria for  BCT in women with  LABC 
are presented in Table 49  
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A prognostic index to estimate the likelihood of an in breast or 
loco  regional  tumor  recurrence  was  developed  in  patients 
undergoing BCT after Neoadjuvant Chemotherapy50
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Unfavorable characteristic are
• Clinical N2 or N3 disease
• Residual pathologic tumor size >2cm
• Multifocal residual disease
• Lymphovascular space invasion
Five  year  survival  rate  of  an  in  breast  recurrence  free 
survival  rate  decreases  when  more  than  two  of  these 
unfavorable  characteristics  present.  If  Breast  conservative 
therapy  is  contemplated,  special  attention  to  be  paid  to  the 
tumors localization before starting Neoadjuvant Chemotherapy 
so that original tumor site can be located if a complete CR is 
achieved  to  neoadjuvant  chemotherapy.  This  can  be 
accomplished  by  inserting  radio  opaque  clip  into  the  central 
portion of the tumour under the guidance of ultrasound prior to 
neoadjuvant chemotherapy BCT is generally not considered as 
an  appropriate  option  for  women  with  inflammatory  breast 
cancer.
AXILLARY STAGING
Regional  Lymph  Nodal  Status  impacts  prognosis  and 
choice  of  therapy.   Majority  of  LABC patients  presents  with 
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palpable nodal disease and in some cases advanced (N2, N3). 
Minority  of  patients  who  are  clinically  node  negative, 
assessment  of  locoregional  nodal  status  is  often  considered 
prior to therapy. Sentinel lymphnode mapping (SLN) and Biopsy 
has  been  integerated  into  the  care  of  early  breast  cancer 
patients with T1, T2 Breast tumor <5cm and T3 with clinically 
node Negative tumor 51 The prognostic information obtained by 
axillary staging after neoadjuvant chemotherapy is equivalent or 
superior to that gained prior to systemic therapy since it permits 
an assessment of response to neoadjuvant chemotherapy.
American Society of Clinical Oncology (ASCO)Guidelines 
suggest that if prognostic information gained from examination 
of the axillary nodes is considered valuable for planning local 
regional  treatment  for  an  individual  patient,  SLNB  can  be 
considered before the institution of systemic therapy in clinically 
node negative patients
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 If  SLN  is  negative,  axillary  lymph  node  dissection  is  not 
preformed at the time of surgery, instead the axilla is irradiated. 
If the SLN is positive, an axillary lymph node dissection is done 
at the time of surgery and the axilla and supraclavicular nodes 
are irradiated only if the nodes are persistently positive .
MANAGEMENT OF NON RESPONDERS 
Failure to respond to neoadjuvant chemotherapy is a poor 
prognostic  sign   particularly  if  disease  progresses  during 
therapy. Approximately  1/3rd remain free of distant disease with 
multidisciplinary  locoregional  management  52  surgery  should 
only be attempted if macroscopically complete resection can be 
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accomplished.  Patients who remain inoperable should receive 
loco  regional  RT   with  subsequent  surgery  if  feasible  53 
Chemotherapy with a non cross resistant regimen is preferred 
option (Taxanes in women who progress during Anthracyclins 
based  therapy.  Hormone  therapy  is  appropriate  for  patient 
whom tumors are ER positive.
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Treatment algorithm for locally advanced breast cancer.
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PATIENTS AND METHODS
Out of all Breast Cancer patients who attends surgical out 
patient  department,  39  patients  who  presented  with  locally 
advanced breast cancer patients 30 patients were enrolled in 
our study.  Each patient was examined to confirm the diagnosis 
of  LABC and to evaluate the clinical stage of the disease at 
presentation and the response to chemotherapy.  The staging 
work  up  included  a  complete  history,  physical  examination, 
complete blood cell count, blood chemical analysis, ECG, chest 
radiograph,  abdominal  ultrasound  and  diagnosis  established 
with fine needle aspiration biopsy from the tumor and involved 
axillary lymph nodes.
Four cycles of induction chemotherapy was administered 
at 18-21 days interval.  The regimen (AC regimen) used were 
Inj.  Adriamycin 50-60mgm/m2 and Inj.  Cyclophosphamide 600-
900 mgm/m2 as 24 hrs continuous IV infusion  on the day 1. 
Clinical responses and  examinations was done on every visit 
for induction  chemotherapy. 
All  patient  underwent  modified  radical  mastectomy with 
axillary  dissection  after  completing  4  cycles  of  neoadjuvant 
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chemotherapy within a period of 3 weeks and the clinical and 
pathological  response  to  the  induction  chemotherapy  was 
evaluated.   These included section from each quadrants and 
the nipple areolar complex.
Postoperatively patients received four more cycles of AC and 
during  each  follow  up,  patient  had  a  history  and  physical 
examination, complete blood count, LFT, serum Calcium ,and if 
the patients symptomatic or suspicious , chest X-ray X ray spine 
or long bones. USG abdomen done every 2 months.
9  patients  were  excluded  from the  study  because  one 
patient  died  before  surgery,   Two  patients  defaulted  due  to 
intolerance to  chemotherapy and 1  patient  withdrawn  due to 
development of malignant pleural effusion during the course or 
induction chemotherapy. 2 patients violation in the regularity of 
chemotherapy cycles and 3 didn’t turned out for follow up after 
surgery..
Data were analyzed using mean and standard deviation. 
Paired t-test was used to compare the reduction in tumor size 
and regression in  number of  axillary lymph node metastasis. 
Life table and Kaplan meier methods were used to estimate the 
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disease  free  survival  ship.  Data  were  analysed  using  SSPS 
(11.5version). 
                     Table.1. Age at Presentation 
Study 
group
Number  of 
patients
Percenta
ge
40-49 9 30%
50-59 15 50%
>60 6 20%
In our study group patients ranges from 40-65 yrs and the 
median age  is 52 yrs. Maximum  number of patients were in 
the range of 50-60 yrs.
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Table 2.Menopausal Status
Study Group Number of 
patients
Percenta
ge
Pre-
menopausal
9 30%
Post-
menopausal
21 70%
CHART.2
MENOPAUSAL STATUS
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Table.3.Side and quadrant of breast lesion
Quadrant  with 
side
Number of 
patients
RUO 8
RLO 3
RUI 4
RLI 1
CENTRAL 2
LUO 5
LLO 2
LUI 2
LLI 1
CENTRAL 2
In our study group most of the patient post menopausal 
and upper outer  quadrant is the most common site of index 
lesion.  
Table  4  lists  the  clinical  characteristics  for  the  30 
assessable pretreatment patients. Most  of the patients in our 
study groups were presented with stage III with 60% stage IIIA 
and  39%  with  stage  IIIB  patients.  80% of  locally  advanced 
breast cancer patients showed N1 disease in our study group. 
The mean tumor size is 7.96cms and the no of lymph nodes is 
4.26.
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CHART.3
CLINICAL CHARACTERISTICS OF
THE PRETREATMENT PATIENTS
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Table  4.  clinical  characteristics  of  the  pretreatment 
patients
 Characteristics of the patients. No of patients
Initial tumor size
T3 19
T4 11
Initial nodal status
N0 2
N1 24
N2 4
Initial stage
II B 1
IIIA 18
IIIB 11
T3N0M0 1
T3N1M0 16
T3N2M0 2
T4N0M0 1
T4N1M0 8
T4N2M0 2
CHART.4
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Primary Tumor Axillary Node
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The clinicopathological responses in breast and axillary lymph 
nodes to induction chemotherapy was analyzed with respect to 
the initial tumor and lymph nodal status and was shown in the 
tabular column.
Table.5.Pathologic findings in breast and axillary specimen 
in response to chemotherapy
Primary  tumor No. 
Patients
(%)
Complete  response  (no  residual  invasive 
disease;)
4 13.3
Partial  response  ( 50%  decrease  in  primary 
tumor size) 
(<50% decrease in primary tumor size)
18
4
73.4
No response/stable disease 4 13.4
Axillary nodal findings
Complete response 10 33.4
Partial response 17 56.6
No response 3 10
13% of patients showed complete primary tumor response and 
73%  of  patients  showed  partial  response  to  induction 
chemotherapy. 34%  of patients showed complete axillary nodal 
regression  and  10%  showed  no  response  in  our  study. 
Statistically  analysis  of  data   on  tumor  size  and  number  of 
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axillary  lymph  nodes  before  and  after   administration  of 
induction chemotherapy has shown in the table
Table.6.Statistically analysis
Pre neoadj. Post 
neoadj.
mean SD mean SD T  p.valu
e
Tumor 
size
7.96c
m
1.5
1
3.26c
m
2.4
6
12.9
6
0.00
Nodal 
status 
4.26 0.9
8
1.80c
m
1.7
3
10.7
9
0.00
Relationship  between  the  pathological  primary  tumour 
response  and  axillary  lymph  nodal  were  evaluated  and  the 
results are shown in the  Table.
Table.7.Relationship Between Pathologic Primary Tumor 
Response and Axillary  Lymph Node Status After 
Neoadjuvant Chemotherapy*
Primary Tumor 
Metastatic  Axillary  Lymph 
Nodes 
P 
0 1-3 4 
No. % No. % No. % 
Complete  pathologic 
response
3 75 1 25 0 0 < .01
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Incomplete  pathologic 
response/no response
7 26.9 9 34.6 10 38.5
73
Table.8.  Relationship  of  pathological  primary  tumor  and  axillary  lymph  node 
response to disease free survival after Neoadjuvant therapy.
Pathological response
No. of 
Patients 
Developed 
recurrence
Recurren
ce  Rate
Disease free 
survival rate
Patients with Complete 
response
1 25% 75%
Patients with Partial 
response
9 49% 51%
CHART.5
Relationship of pathological primary tumor and axillary lymph node 
response to disease free survival after Neoadjuvant therapy
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Out of 4 patients who had complete pathological primary tumor 
response  3  patients  had  no  axillary  lymph  nodal  metastasis 
after induction therapy when compared to 7 patients out of 26 
patients  who  had  incomplete  pathological  primary  tumor 
response. At a median follow up of 21 months (ranges from 12 
months to  36 months)  among the patient  who had complete 
pathological  response  there  was  1  patient  with  locoregional 
recurrence  in  contrast  among  the  patients  who  showed 
incomplete pathological responses 8 patients  had locoregional 
recurrences  and  one  patients  developed  malignant  pleural 
effusion  Relationship between pathological primary tumour and 
axillary lymph nodal  response  to disease free survival after 
neoadjuvant  chemotherapy was   analysed  and shown in  the 
table.
The site of locoregional recurrence in both complete and 
incomplete response were shown in the tabular column.
Study group Site Total no of 
patientsScar Tumour 
bed
Axill
a
Distant 
met.
75
Complete 
response
1 - - - 1
Incomplete 
response
3 2 3  1 9
RECURRENT CARCINOMA AT THE SCAR SITE
76
RECURRENT AXILLARY LYMPHNODE METASTASIS WITH 
ARM EDEMA 
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DISCUSSION
Nowadays  locally  advanced  breast  carcinomas  are 
commonly treated with neoadjuvant chemotherapy followed by 
definitive  surgery.  The  results  of  our  study  indicates  that  in 
many patients, neoadjuvant chemotherapy can completely clear 
the  breast  and  axillary  lymph  nodes  of  any  microscopic 
evidence of invasive tumor as assessed by standard histologic 
examination. In our study group this occurred in 4patients (13% 
of patients) after four cycles of AC regimen with over all clinical 
responses to induction therapy in 80% of patients. Powels et al 
and Kuerer et all shown similar results in 10% and !6% of locally 
advanced  breast  carcinoma patients  with  Anthracyclin  based 
Neoadjuvant chemotherapy. Sataloff et al shown similar results 
with 39% of patients with complete clinical response with overall 
clinical responses to induction therapy in 86% and experienced 
significant  shrinkage  of  primary  tumor  there   by  facilitating 
subsequent surgery.
The  study   has  also  been  shown  that  the  induction 
chemotherapy  convert clinically involved axillary nodal disease 
to  a  pathological  negative  status  in   10  patients  (34%).  2 
different studies Hortobagi et al and Fisher et al shown similar 
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response rate of  primary tumor and lymph nodes  in about 35% 
to 40% of locally advanced breast cancer patients.
          One  major  goal  of  systemic  therapy  in  the  early 
eradication of subclinical distant micrometastasis in an attempt 
to improve survival. Theoretically  one could surmise that the 
response of axillary lymph node metastasis to systemic therapy 
might  reflect  the  sensitivity  of  occult  metastasis  in  the  other 
organ compartments. 
In  our  study  of  relationship  between  the  pathological 
primary  tumour  response  and  axillary  lymph  nodal  response 
were  evaluated  and  the  results  shown  that  a  pathological 
complete  primary  tumor   response were  more likely  to  have 
negative axillary lymph node status.75% of patients(n=3 out of 
4) had no axillary lymph node metastasis when compared to 
27% (n=7 out of  26 )of  patients with pathological  incomplete 
primary tumor  response which is statistically significant. Kuerer 
et al had similar results in which 73% of patients had no axillary 
metastasis  in  pathologically  complete  response  with 
improvement in overall and disease free survival. Hyytinen et al 
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and Teixeira et al  also shown similar results in their series of 
studies.
Results  of  our  study  also  shows  that  the  patients  with 
complete pathological response  in primary tumor and axillary 
lymphnode  had significant fewer recurrence (n=1) 25% than did 
the  patients  with  an  incomplete  response  (n=9)49%.  and 
significant higher disease free survival 75% than the patients 
with an incomplete response  51% and the p value for both is 
<0.01. NSABP B-18 and other trials has shown similar results 
and conclusively proven better disease free survival rates and 
over all  survival rates in pathological complete primary tumor 
response and axillary lymphnode  in 80-85% of patients than 
patients  with  an  incomplete  response  to  neoadjuvant 
chemotherapy  ranges from 55-65% .
In our study the follow up period was only  3 years with 
median follow up period of  21 months and probably 5 years 
disease free survival and overall survival rates may be on par 
with this short study and it is too early to comment on it. 
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SUMMARY
Neoadjuvant  chemotherapy   totally  eradicated  the 
histologic evidence of invasive cancer in both the primary breast 
tumor and axillary lymphnode in approximately 13% of locally 
advanced breast  carcinoma patients who receive 4 cycles of 
induction chemotherapy with overall response in about 80% of 
the patients.
Patients  with  complete  pathological  primary  tumor 
response  were  more  likely  to  have  no  axillary  lymph  node 
metastasis  in  75%  of  patients  compared  with  the  patients 
having partial pathological response in the primary tumor after 
induction chemotherapy.
Patients  with  complete  pathological  response  in  both 
primary  tumor  and  axillary  lymph  nodes  had  decreased 
recurrence rate with significant improved disease free survival 
when  compared  to  the  patients  with  partial  pathological 
response
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CONCLUSION
The   results  from  our  study  suggest  that  the  maximal 
tumor shrinkage and sterilization of potentially involved axillary 
lymph  nodes  after  the  induction  chemotherapy  in  locally 
advanced breast cancer patients rendered surgically resectable 
in  most  number  of  patients..  Our  studies  also  shown  that 
complete regression in number of metastatic lymph nodes  in 
complete pathological primary tumor response associated with 
eradication of distant occult  metastasis which is an important 
prognostic factor and shows significant improvement in disease 
free  survival  of  breast  cancer  patients.   The   above  result 
suggest  that  Neoadjuvant  chemotherapy  is  the  standard 
management  in  patients  with  locally  advanced  breast 
carcinoma.  But  prediction  of  response  to  induction 
chemotherapy in breast cancers remains to be determined and 
many studies recently focused on potential biological markers 
which influence the  response to induction chemotherapy.
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COIMBATORE MEDICAL COLLEGE HOSPITAL
A STUDY ON CLINICOPATHOLOGICAL RESPONSE 
TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY 
ADVANCED BREAST CARCINOMA
PROFORMA
Name : Age: Sex: IP.no:
Address:         
Occupation:
Socioeconomic status.
CLINICAL HISTORY  
1.Presenting symptoms
1.Swelling
2.Pain.
3.Nipple discharge
4.Nipple retraction
5.Loss of appetite and weight.
6.Inflammatory symptoms
Systemic: i}Pyrexia
     ii}Sweating
     iii}Malaise
     Local: i} Pain
     ii}Change in colour
     iii}Edema
     iv}Cellulitis.
7.Symptoms suggestive of metastasis.
i}Back pain
ii}Head ache and convulsion
iii}Chest symptoms
iv}Jaundice
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v}Opposite breast Swelling
2.Past history:
H/o associated medical conditions like HT/DM/IHD/TB
H/o similar swelling in the breast.
H/o surgery for benign breast disease
3. Family history:
H/o breast cancer in 1st degree relative
4. Drug history
H/o OCP intake/HRT.
H/o previous exposure to radiation
5. Menstrual history
Age at menarche
Age at menopause
Alterations in cycles.
6. Marital history
Age at marriage:
7.Obstetric history
Parity:
Age of the patient at 1st child birth:
Age of patient at last child birth:
History and duration of breast feeding:
8.Personal history
H/o smoking and alcohol:.
Dietetic history:
EXAMINATION
PRE INDUCTION CHEMOTHERAPY STATUS
General examination: 
Built/pallor/icterus/pedaledema/lymphadenopathy
Local examination.
Breast: A. Side and Quadrant involved 
  B. Tumour size
  C. Axillary nodal status
  E. Opposite breast/opposite axilla
Other systems
Abdomen:
Cardiovascular system:
Respiratory system:
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Central nervous system:
Spine and Cranium:
INVESTIGATIONS:
1.FNAC Biopsy.
2.Hematological parameter
3. X-ray Chest
4. USG Abdomen and pelvis
5..ECG.
STAGING:.
NEOADJUVANT CHEMOTHERAPY:
Type of regimen:
Patient details on each cycle -Tumor status 
      -Axillary lymphnodal status.
      -Any symptoms and signs of 
metastasis.
No. of cycles
TREATMENT
Type of surgery
POST INDUCTION CHEMOTHERAPY STATUS
HISTOPATHOLOGY 
Primary Tumor
-Macroscopic features
-Histological features
Axillary nodal status.
POST OPERATIVE ADJUVANT CHEMOTHERAPY
Duration after surgery
Type of regimen:
 No. of cycles:
FOLLOW UP:
Complaints: 
Nodule/Swelling
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                                  i}Single/multiple
                                 ii}Chest wall
                                 iii}Axilla
                                 iv}Supraclavicular region
Ulcerations
Arm edema
Symptoms suggestive of metastasis
General examination
Local Examination
Swelling/ulcer
Operative Scar
Tumour bed
Axilla 
Supraclavicular region
Arm edema 
Distant metastatic sites
Bone
Lungs and pleura
Brain
Liver
Peritoneal & Krukenburg tumor
Opposite breast and Axilla
INVESTIGATIONS:
Basic investigations
Hematological parameter
Specific investigations
1.FNAC/ Biopsy if any recurrence
2. serum Calcium /serum alkaline 
phosphatase
3.. Liver function test
4. X-ray Chest/spine
5..USG Abdomen and pelvis
6.CT Scan if needed.
DISEASE FREE INTERVAL.
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MASTER CHART
Sl. 
No.
Name Age / 
Sex
IP 
No.
Menst. Side & 
quadra
nt
T
S
AN Stage CH T
S
AN Surgery RE DFS
1 Valliammal 58 / F 6450 Post RUO 7 4 T3N2M0 AC 0 2 MRM & AC - 14.5
2 Ponnammal 52 / f 1320 Post RUO 9 4 T3N1M0 AC 3 2 MRM & AC - 19.5
3 Thenmozhi 38 / F 1213
4
Post RC 7 6 T3N1M0 AC 3 4 MRM & AC - 21
4 Mariammal 55 / F 1612
0
Post RUI 7 3 T3N1M0 AC 3 0 MRM & AC - 20
5 Maniammal 52 / F 1324
0
Post RC 10 6 T3N1M0 AC 3 4 MRM & AC - 21
6 Santhadevi 45 / F 1531
0
Pre RLO 9 3 T3N1M0 AC 2 3 MRM & AC - 25
7 Subbammal 54 / F 1123
4
Post LUO 10 5 T3N2M0 AC 7 4 MRM & AC + 28
8 Nagammel 60 / F 1231 Post LUO 8 5 T3N1M0 AC 2 2 MRM & AC - 29
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Sl. 
No.
Name Age / 
Sex
IP 
No.
Menst. Side & 
quadra
nt
T
S
AN Stage CH T
S
AN Surgery RE DFS
0
9 Suseela 58 / F 1211
0
Post RLO 6 4 T4N1M0 AC 1 1 MRM & AC + 31.5
10 Mary 43 / F 1314
1
Pre LLI 8 4 T3N1M0 AC 3 0 MRM & AC - 20
11 Saradha 45 / F 9678 Post RUI 11 4 T3N1M0 AC 6 4 MRM & AC - 21
12 Vellammal 65 / F 9780 Post LLO 7 4 T4N1M0 AC 3 0 MRM & AC - 20.5
13 Laxmi 46 / F 7678 Pre RUO 8 4 T3N1M0 AC 2 0 MRM & AC - 17
14 Manonmani 52 / F 1165
8
Post RUO 9 3 T3N1M0 AC 4 1 MRM & AC - 12
15 Jeyalakshmi 50 / F 1007
6
Pre RUO 6 3 T3N1M0 AC 0 0 MRM & AC - 32.5
16 Parvathi 50 / F 1024
5
Pre LC 5 4 T4N1M0 AC 1 1 MRM & AC + 33.5
17 Vijaya 48 / F 1711 Post LUI 10 5 T4N1M0 AC 9 4 MRM & AC + 33
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8
18 Meenakchi 46 / F 1278
7
Pre LLO 8 6 T4N1M0 AC 6 4 MRM & AC - 32
19 Subbathal 60 / F 7447 Post LUI 8 4 T4NIM0 AC 8 5 MRM & AC + 32
20 Akkammal 61 / F 2233
1
Post LC 9 5 T4N1M0 AC 7 5 MRM & AC + 30
21 Saraswathi 56 / F 7176 Post LUO 5 5 T4N1M0 AC 2 2 MRM & AC + 32
22 Radha 45 / F 1147
5
Pre LUO 7 4 T3N1M0 AC 2 1 MRM & AC + 30
23 Kannammal 60 / F 1711
8
Post LUO 9 5 T4N2M0 AC 2 4 MRM & AC - 28.5
24 Sivagami 56 / F 1277
8
Post RLO 10 6 T3N1M0 AC 6 4 MRM & AC - 26.5
25 Pappathi 40 / F 1214
7
Pre RLI 8 0 T3N0M0 AC 2 0 MRM & AC - 21
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26 Shanthi 48 / F 6467 Post RUI 9 3 T3N1M0 AC 5 1 MRM & AC - 19
27 Petchiamma
l
51 / F 5467 Post RUI 6 0 T4N0M0 AC 2 0 MRM & AC - 13
28 Dhanalaksh
mi
50 / F 1511
7
Pre RUO 7 3 T3N1M0 AC 4 1 MRM & AC - 20
29 Pappaye 62 / F 1477
8
Post RUO 8 4 T4N2M0 AC 0 0 MRM & AC + 34
30 Ponnammal 55 / F 1254
6
Post RUO 8 5 T3N1M0 AC 0 0 MRM & AC - 18
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Menst - Menopausal Status LLI - Left Lower Inner
TS - Tumour size MRM & AC - Modified Radical Mastectomy and Axillary Clearance 
AN - Axillary Node RC - Right central.
CH - Chemotherapy Regimen LC -           Left central.
RE - Recurrence  
DFS - Disease Free Survival in months
RUO - Right Upper Outer
RUI - Right Upper Inner
LUO - Lower Upper Outer
LUI - Right Upper Outer
RLO - Right Lower Outer
RLI - Right Lower Inner
LLO - Left Lower Outer
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